|
|
Article: Investigators Present Long-Term TOBI Data at Cystic Fibrosis Conference; Lung Function Improvements Were Maintained.
- Article from:
- PR Newswire
- Article date:
- October 16, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MONTREAL, Oct. 16 /PRNewswire/ -- Investigators today reported 18-month clinical trial data on TOBI(R) (tobramycin solution for inhalation) at the North American Cystic Fibrosis Conference. Marketed by PathoGenesis Corp. (Nasdaq: PGNS), TOBI is approved in the U.S. for management of cystic fibrosis patients with Pseudomonas aeruginosa.
Among the important findings of the TOBI 18-month data:
-- Cystic fibrosis patients continued to maintain improved lung function
above baseline values after 18 months of the chronic intermittent TOBI
treatment regimen -- 28 days on drug, 28 days off drug. After 18
months, previously published ...